# US 2015/0105335 A1 · Novel peptide compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105335 A1
- Document ID: US20150105335A1
- Status: Published application
- Kind: A1
- Application number: 14/506,497
- Filed: 2014-10-03
- Published: 2015-04-16
- Earliest claimed: 2013-10-11
- Assignees: Tarix Pharmaceuticals Ltd.
- Applicants: Tarix Pharmaceuticals Ltd.
- Inventors: Richard Franklin
- Web page: https://patentgrep.com/patent/US20150105335A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 7/14: Angiotensins: Related peptides
- C07K 7/64: Cyclic peptides containing only normal peptide links
- C07K 14/47: from mammals
- C07K 14/475: Growth factors; Growth regulators
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides, among other things, novel peptides and compositions for treating disease.

## Claims

### Claim 1

A peptide comprising an amino acid sequence according to formula I:
(SEQ ID NO: 1)
Ala1-Xaa2-Xaa3-Ser4-Xaa5-Xaa6-Cys7
wherein
Xaa2 is selected from Arg, Lys, Ala, Cit (citrulline), Orn (ornithine), acetylated Ser, Sar, D-Arg and D-Lys;
Xaa3 is selected from Val, Ala, Leu, Nle, Ile, Gly, Lys, Pro, Aib (2-aminoisobutyric acid), Acpc (1-aminocyclopentane carboxylic acid) and Tyr;
Xaa5 is selected from Ile, Ala, Leu, norLeu, Val and Gly; and
Xaa6 is selected from His, Arg and 6-NH2-Phe (6-aminophenylalanine).

### Claim 2 (depends on 1)

The peptide of claim 1, wherein the peptide contains between 7 and 25 amino acids, inclusive.

### Claim 3 (depends on 1)

The peptide of claim 1, wherein the peptide comprises one or more chemical modifications to increase protease resistance, serum stability, and/or bioavailability.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising a peptide according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the pharmaceutical composition is formulated for oral, intramuscular, intravenous, subcutaneous, topical, transdermal, rectal, vaginal, pulmonary, intranasal, intrabuccal, or sublingual administration.

### Claim 6 (depends on 4)

The pharmaceutical composition of claim 4, wherein the pharmaceutical composition further comprises one or more pharmacologically acceptable excipients selected from a polymer carrier, a disintegration agent, a lubricant, a solvent, or a swelling agent.

### Claim 7 (depends on 4)

The pharmaceutical composition of claim 4, wherein the pharmaceutical composition is formulated as a tablet, pill, capsule, granules, a syrup, a spray, an aerosol, a liposomal composition, an ointment, a suppository, an implant, a plaster, or a slow release formulation.

### Claim 8 (depends on 1)

A method of treating a disease, condition, or disorder comprising:
administering to a subject in need thereof a peptide or composition according to claim 1.

### Claim 9

A peptide comprising the amino acid sequence Ala1-Arg2-Val3-Ser4-Ile5-His6-Cys7 (SEQ ID NO: 18).

### Claim 10 (depends on 9)

The peptide of claim 9, wherein the peptide comprises one or more chemical modifications to increase protease resistance, serum stability, and/or bioavailability.

### Claim 11 (depends on 9)

A pharmaceutical composition comprising a peptide according to claim 9 and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein the pharmaceutical composition is formulated for oral, intramuscular, intravenous, subcutaneous, topical, transdermal, rectal, vaginal, pulmonary, intranasal, intrabuccal, or sublingual administration.

### Claim 13 (depends on 11)

The pharmaceutical composition of claim 11, wherein the pharmaceutical composition further comprises one or more pharmacologically acceptable excipients selected from a polymer carrier, a disintegration agent, a lubricant, a solvent, or a swelling agent.

### Claim 14 (depends on 11)

The pharmaceutical composition of claim 11, wherein the pharmaceutical composition is formulated as a tablet, pill, capsule, granules, a syrup, a spray, an aerosol, a liposomal composition, an ointment, a suppository, an implant, a plaster, or a slow release formulation.

### Claim 15 (depends on 9)

A method of treating a disease, condition, or disorder comprising:
administering to a subject in need thereof a peptide or composition according to claim 9.

### Claim 16

(canceled)

### Claim 17 (depends on 15)

The method of claim 15, wherein the disease, condition, or disorder is stroke.

### Claim 18

(canceled)
